TW200630381A - Tumor endothelial marker-1 (TEM1) binding antibodies and uses thereof - Google Patents

Tumor endothelial marker-1 (TEM1) binding antibodies and uses thereof

Info

Publication number
TW200630381A
TW200630381A TW094126909A TW94126909A TW200630381A TW 200630381 A TW200630381 A TW 200630381A TW 094126909 A TW094126909 A TW 094126909A TW 94126909 A TW94126909 A TW 94126909A TW 200630381 A TW200630381 A TW 200630381A
Authority
TW
Taiwan
Prior art keywords
antibodies
tem1
endothelial
disclosed
endothelial marker
Prior art date
Application number
TW094126909A
Other languages
Chinese (zh)
Inventor
Beverly Teicher
Bruce Roberts
Shiro Kataoka
Tomoyuki Tahara
Nakayuki Honma
Original Assignee
Kirin Brewery
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery, Genzyme Corp filed Critical Kirin Brewery
Publication of TW200630381A publication Critical patent/TW200630381A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to antibodies that bind tumor endothelial marker 1 (TEM1) and effectively inhibit angiogenesis, tumor growth, or both. Pharmaceutical compositions and uses thereof for the treatment of angiogenesis-associated diseases including cancer, polycystic kidney disease, diabetic retinopathy, age-related macular degenerations, rheumatoid arthritis, and psoriasis are also disclosed. Also disclosed are methods of identifying such antibodies by assessing (1) the inhibitory activity of candidate antibodies in proliferation and tube formation assays using endothelial cells, endothelial precursor cells and pericytes, and (2) the antibody-dependent cellular cytotoxic, phagocytosis, and complement-dependent cytotoxic activities of candidate antibodies.
TW094126909A 2004-08-05 2005-08-08 Tumor endothelial marker-1 (TEM1) binding antibodies and uses thereof TW200630381A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59935904P 2004-08-05 2004-08-05

Publications (1)

Publication Number Publication Date
TW200630381A true TW200630381A (en) 2006-09-01

Family

ID=35839950

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094126909A TW200630381A (en) 2004-08-05 2005-08-08 Tumor endothelial marker-1 (TEM1) binding antibodies and uses thereof

Country Status (2)

Country Link
TW (1) TW200630381A (en)
WO (1) WO2006017759A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
CA2607455A1 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
CN101089178B (en) * 2006-06-12 2012-05-23 杭州北斗生物技术有限公司 Beta-lactamase and its prepn process and application
BRPI0809665B8 (en) 2007-04-05 2021-05-25 Eisai Inc monoclonal antibody that specifically binds to endosialin
WO2010037124A1 (en) 2008-09-29 2010-04-01 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
US20120034228A1 (en) 2008-10-01 2012-02-09 Micromet Ag CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
US9556272B2 (en) 2009-11-11 2017-01-31 The Trustees Of The University Of Pennsylvania Anti-TEM1 antibodies and uses thereof
US20130130373A1 (en) * 2011-11-11 2013-05-23 Essential Pharmaceuticals, Llc Kit Comprising Serum Replacement and Labile Factors
EP3543258B1 (en) * 2012-03-30 2023-09-13 Eisai R&D Management Co., Ltd. Tem-1 diagnostic antibodies
WO2013162748A1 (en) * 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
WO2016205618A1 (en) * 2015-06-19 2016-12-22 Morphotek, Inc. Cys80 conjugated immunoglobulins
EP3202788A1 (en) * 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialin-binding antibody
CN106591208A (en) * 2016-12-07 2017-04-26 南昌大学 Vector strain of recombinant single-chain antibody expressing DNase I, AIF or integrating toxins, and application of strain
GB201702926D0 (en) * 2017-02-23 2017-04-12 Univ Birmingham Modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
EP1578947A4 (en) * 2002-12-02 2006-12-06 Abgenix Inc Antibodies directed to phospholipase a2 and uses thereof
JP4234754B2 (en) * 2003-02-21 2009-03-04 ノル・インコーポレイテッド Mechanical arm with balancing spring
US20050266008A1 (en) * 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies

Also Published As

Publication number Publication date
WO2006017759A2 (en) 2006-02-16
WO2006017759A3 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
TW200630381A (en) Tumor endothelial marker-1 (TEM1) binding antibodies and uses thereof
TWI696635B (en) Novel modulators and methods of use
JP5766296B2 (en) Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
MX2010005966A (en) Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7).
ATE551071T1 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATION AND AUTOIMMUNE DISEASES
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
MY151191A (en) Novel antibodies
WO2005054273A3 (en) Humanized antibodies against vascular endothelial growth factor
MX2012004084A (en) Siglec 15 antibodies in treating bone loss-related disease.
EP3186278A1 (en) Internalizing moieties for treatment of cancer
WO2006099875A8 (en) Antibodies against cd38 for treatment of multiple myeloma
MEP10609A (en) Novel anti-cd38 antibodies for the treatment of cancer
ATE459653T1 (en) MONOCLONAL ANTI-CD71 ANTIBODIES AND THEIR USE FOR TREATING MALIGNANT TUMOR CELLS
WO2014012007A4 (en) Rspo3 binding agents and uses thereof
WO2006089141A3 (en) Antibodies against cxcr4 and methods of use thereof
MX2007000023A (en) Interferon alpha receptor 1 antibodies and their uses.
CN107787331A (en) Anti-HER 2 and application method
MY159375A (en) Combinatorial therapy
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
UA99602C2 (en) Antibody that specifically binds to jam-a, capable of inhibiting the proliferation of tumor cells
HRP20210410T1 (en) Conjugated antibodies against ly75 for the treatment of cancer
CN109535253A (en) Novel anti-CD 19 antibodies
WO2014132647A1 (en) Antibody, fragment, pharmaceutical composition, molecule, and tumor marker
WO2005086713A3 (en) Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
HK1116198A1 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth